share_log

Jefferies Upgrades GSK to Buy, Raises Price Target to $48

Benzinga ·  Jan 3 18:46

Jefferies analyst Peter Welford upgrades GSK (NYSE:GSK) from Hold to Buy and raises the price target from $38.5 to $48.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment